<DOC>
	<DOC>NCT00111631</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patients 1875 years of age; type 2 diabetes; stable metformin therapy for &gt;=3 months before screening. women who are pregnant, breastfeeding, or not using an adequate contraceptive method; type 1 diabetes; any antihyperglycemic medication other than metformin in the last 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>